Dana M Fowlkes

Dana is a graduate of Cornell University Graduate School of the Medical Sciences and Cornell University Medical College. Previously he was a Venture Partner at Hatteras Venture Partners as well as Executive VP and CSO at Karo Bio AB. Dana co-founded Cadus Pharmaceutical Corp and Novalon Pharmaceutical Corp. where he negotiated the company’s $107 million mergers with Karo Bio AB. Dana’s scientific and medical interests have focused on phage display and drug screening technologies. His goal for Evrys Bio is to establish partnerships to advance the company’s drugs into clinical trials for indications such as Hepatitis B, influenza-like illnesses, and areas needing broad-spectrum antiviral activity.